Bayer Free Cash Flow 2010-2024 | BAYRY
Bayer annual/quarterly free cash flow history and growth rate from 2010 to 2024. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
- Bayer free cash flow for the quarter ending December 31, 2024 was 5,286.06, a year-over-year.
- Bayer free cash flow for the twelve months ending December 31, 2024 was , a year-over-year.
- Bayer annual free cash flow for 2024 was $5.286B, a 89.23% increase from 2023.
- Bayer annual free cash flow for 2023 was $2.793B, a 49.73% decline from 2022.
- Bayer annual free cash flow for 2022 was $5.557B, a 64.74% increase from 2021.
| Bayer Annual Free Cash Flow |
| 2024 |
5,286.06 |
| 2023 |
2,793.42 |
| 2022 |
5,556.69 |
| 2021 |
3,373.02 |
| 2020 |
3,214.43 |
| 2019 |
6,540.80 |
| 2018 |
6,559.27 |
| 2017 |
6,791.97 |
| 2016 |
7,327.91 |
| 2015 |
5,070.09 |
| 2014 |
4,761.55 |
| 2013 |
4,206.73 |
| 2012 |
3,639.66 |
| 2011 |
5,181.21 |
| 2010 |
5,736.53 |
| 2009 |
5,436.15 |
| Bayer Quarterly Free Cash Flow |
| 2024-12-31 |
5,286.06 |
| 2024-09-30 |
917.07 |
| 2024-06-30 |
-767.83 |
| 2024-03-31 |
-2,714.25 |
| 2023-12-31 |
2,793.42 |
| 2023-09-30 |
-2,321.56 |
| 2023-06-30 |
-4,400.85 |
| 2023-03-31 |
-4,265.69 |
| 2022-12-31 |
5,556.69 |
| 2022-09-30 |
3,029.66 |
| 2022-06-30 |
996.09 |
| 2022-03-31 |
-986.41 |
| 2021-12-31 |
3,373.02 |
| 2021-09-30 |
1,035.34 |
| 2021-06-30 |
-1,588.06 |
| 2021-03-31 |
-3,540.85 |
| 2020-12-31 |
3,214.43 |
| 2020-09-30 |
3,346.85 |
| 2020-06-30 |
1,464.46 |
| 2020-03-31 |
-640.96 |
| 2019-12-31 |
6,540.80 |
| 2019-09-30 |
3,829.73 |
| 2019-06-30 |
2,125.48 |
| 2019-03-31 |
792.79 |
| 2018-12-31 |
6,559.27 |
| 2018-09-30 |
4,198.51 |
| 2018-06-30 |
2,590.33 |
| 2018-03-31 |
452.35 |
| 2017-12-31 |
6,791.97 |
| 2017-09-30 |
5,389.93 |
| 2017-06-30 |
2,569.37 |
| 2017-03-31 |
1,044.39 |
| 2016-12-31 |
7,327.91 |
| 2016-09-30 |
2,690.68 |
| 2016-06-30 |
2,700.87 |
| 2016-03-31 |
1,081.14 |
| 2015-12-31 |
5,070.09 |
| 2015-09-30 |
3,979.77 |
| 2015-06-30 |
2,014.39 |
| 2015-03-31 |
456.00 |
| 2014-12-31 |
4,761.55 |
| 2014-09-30 |
2,957.66 |
| 2014-06-30 |
1,274.40 |
| 2014-03-31 |
-243.95 |
| 2013-12-31 |
4,206.73 |
| 2013-09-30 |
3,085.23 |
| 2013-06-30 |
1,380.34 |
| 2013-03-31 |
-14.53 |
| 2012-12-31 |
3,639.66 |
| 2012-09-30 |
3,179.81 |
| 2012-06-30 |
1,281.25 |
| 2012-03-31 |
48.51 |
| 2011-12-31 |
5,181.21 |
| 2011-09-30 |
4,399.20 |
| 2011-06-30 |
2,676.35 |
| 2011-03-31 |
838.03 |
| 2010-12-31 |
5,736.53 |
| 2010-09-30 |
3,718.35 |
| 2010-06-30 |
2,178.30 |
| 2010-03-31 |
713.58 |
| 2009-12-31 |
5,436.15 |
| 2009-09-30 |
3,681.62 |
| 2009-06-30 |
1,981.86 |
| 2009-03-31 |
546.74 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$30.927B |
$50.438B |
|
Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses. The company started reporting in three segments ' Pharmaceuticals, Consumer Health and Crop Science ' from the third quarter of 2019. Both Animal Health and Currenta were reported as discontinued operations in the quarter. The company acquired U.S. seed giant Monsanto in June, 2018. With the acquisition, Bayer now has the strongest portfolio of seed and crop protection products for a wide range of crops and indications, the best research and development platform and the leading digital farming business.
|
